Business Wire

IQM Announces Major Upgrade to Resonance Quantum Cloud Platform With New Software Development Kit

10.7.2025 10:09:00 CEST | Business Wire | Press Release

Share

IQM Quantum Computers, a global leader in building quantum computers, today announced a major upgrade to its quantum computing cloud platform, IQM Resonance, to accelerate the development of quantum algorithms with new software tools and provide end-users with a powerful new quantum system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710268218/en/

IQM Resonance

The upgrade features Qrisp – a project started at Fraunhofer FOKUS – as the new default software development kit (SDK). Qrisp offers a highly powerful but easy to learn higher level programming interface for quantum developers and researchers. The Qrisp framework is and stays open source.

With the new software development kit becoming the default, IQM continues to support other popular quantum programming frameworks such as Qiskit, Cirq, Cuda Quantum, and TKET ensuring flexibility for all users. IQM’s comprehensive and open approach to quantum development builds a powerful foundation catering for both experienced and new quantum developers.

IQM has also appointed Raphael Seidel as Lead Quantum Software Engineer for Qrisp at IQM, to lead the next steps in Qrisp development beginning in October 2025. “Starting from grassroots efforts, Qrisp has demonstrated again and again that the underlying programming model brings serious performance advantages. From raw gate-counts to compiler scaling, Qrisp is state-of-the-art in quantum programming. A direct and strong integration into IQM’s physical quantum hardware will mark the next chapter of the framework and grants a strong head-start into the era of fault-tolerant quantum computers,” said Seidel.

Other key updates to the IQM Resonance platform include:

  • Advanced error handling: The platform now supports error suppression and mitigation technologies. The first features include dynamical decoupling to protect qubits from environmental noise with readout error mitigation to improve the accuracy of experimental results coming next, allowing users to get more precise and reliable data from their quantum computations.
  • Accelerated research with advanced libraries and resources: The platform also introduces a powerful Quantum Approximate Optimization Algorithm (QAOA) library. This key application library allows researchers to efficiently create, test, and optimize quantum circuits for complex optimization problems with a variety of different QAOA flavours, enabling rapid iteration on novel ideas.
  • Expanded IQM Academy resources: IQM Academy now features comprehensive examples and tutorials for Qrisp and a new dedicated section on error reduction, also providing insights into IQM's upcoming Noise Robust estimation techniques. Furthermore, a dedicated lecture series using Qrisp on IQM hardware will be available soon.
  • Pulse-Level Access: For advanced users seeking maximum experimental control, IQM Resonance now offers pulse-level access. This allows researchers to directly program pulse schedules, enabling fine-tuned experiments and the development of novel quantum operations.

To broaden access to its world-class platform, IQM also opens Starter tier, a free charge plan open for any end user. The new tier provides users with up to 30 credits per month on selected IQM quantum computers, removing barriers for students, researchers, and developers to start their quantum journey. To mark the debut of the Starter Tier and the availability of IQM Crystal 54, IQM is also extending access to the 54-qubit quantum computer to all Starter tier users for a limited time.

"We are entering a new era of utility for quantum computing, and these updates to IQM Resonance are a testament to our commitment to empowering the ecosystem," said Dr. Stefan Seegerer, Head of Product, Quantum Platform at IQM. "By making our Crystal 54-qubit system available, integrating error reduction techniques, and standardizing on Qrisp, we are providing the tools researchers and developers need to push the boundaries of what's possible. The new free Starter plan is a crucial step in our mission to make quantum technology accessible to everyone."

About IQM Quantum Computers:

IQM is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers. IQM customers include the leading high-performance computing centres, research labs, universities and enterprises which have full access to IQM's software and hardware. IQM has over 300 employees with headquarters in Finland and a global presence in France, Germany, Italy, Japan, Poland, Spain, Singapore, South Korea and the United States.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250710268218/en/

Contacts

Media contact:
Email: press@meetiqm.com
Mobile: +358504790845
www.meetiqm.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.meetiqm.com
%2F&esheet=54288575&newsitemid=20250710268218&lan=en-US&anchor=www.meetiqm.com&i
ndex=2&md5=94b812987bddc37aa87e9cf6cad6d86d

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye